172 related articles for article (PubMed ID: 8004758)
41. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
[TBL] [Abstract][Full Text] [Related]
42. Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel.
Withoff S; Keith WN; Knol AJ; Coutts JC; Hoare SF; Mulder NH; de Vries EG
Br J Cancer; 1996 Aug; 74(4):502-7. PubMed ID: 8761362
[TBL] [Abstract][Full Text] [Related]
43. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
Prost S; Riou G
Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110
[TBL] [Abstract][Full Text] [Related]
44. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin.
Mirski SE; Gerlach JH; Cole SP
Cancer Res; 1987 May; 47(10):2594-8. PubMed ID: 2436751
[TBL] [Abstract][Full Text] [Related]
45. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene.
Lorico A; Rappa G; Srimatkandada S; Catapano CV; Fernandes DJ; Germino JF; Sartorelli AC
Cancer Res; 1995 Oct; 55(19):4352-60. PubMed ID: 7671247
[TBL] [Abstract][Full Text] [Related]
46. A drug-resistant variant of topoisomerase II alpha in human HL-60 cells exhibits alterations in catalytic pH optimum, DNA binding and sub-nuclear distribution.
Boege F; Kjeldsen E; Gieseler F; Alsner J; Biersack H
Eur J Biochem; 1993 Dec; 218(2):575-84. PubMed ID: 8269948
[TBL] [Abstract][Full Text] [Related]
47. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.
Danks MK; Schmidt CA; Cirtain MC; Suttle DP; Beck WT
Biochemistry; 1988 Nov; 27(24):8861-9. PubMed ID: 2853972
[TBL] [Abstract][Full Text] [Related]
48. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
49. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line.
Webb CD; Latham MD; Lock RB; Sullivan DM
Cancer Res; 1991 Dec; 51(24):6543-9. PubMed ID: 1660341
[TBL] [Abstract][Full Text] [Related]
50. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
de Jong S; Zijlstra JG; de Vries EG; Mulder NH
Cancer Res; 1990 Jan; 50(2):304-9. PubMed ID: 1967222
[TBL] [Abstract][Full Text] [Related]
51. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148
[TBL] [Abstract][Full Text] [Related]
52. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
53. Etoposide-induced DNA damage in human tumor cells: requirement for cellular activating factors.
Sinha BK; Eliot HM
Biochim Biophys Acta; 1991 Sep; 1097(2):111-6. PubMed ID: 1655044
[TBL] [Abstract][Full Text] [Related]
54. Decreased levels of topoisomerase II alpha in human renal cell carcinoma lines resistant to etoposide.
Scheltema JM; Romijn JC; van Steenbrugge GJ; Beck WT; Schröder FH; Mickisch GH
J Cancer Res Clin Oncol; 1997; 123(10):546-54. PubMed ID: 9393588
[TBL] [Abstract][Full Text] [Related]
55. A novel mutant topoisomerase II alpha present in VP-16-resistant human melanoma cell lines has a deletion of alanine 429.
Campain JA; Gottesman MM; Pastan I
Biochemistry; 1994 Sep; 33(37):11327-32. PubMed ID: 7727383
[TBL] [Abstract][Full Text] [Related]
56. A truncated cytoplasmic topoisomerase IIalpha in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34.
Mirski SE; Sparks KE; Yu Q; Lang AJ; Jain N; Campling BG; Cole SP
Int J Cancer; 2000 Feb; 85(4):534-9. PubMed ID: 10699927
[TBL] [Abstract][Full Text] [Related]
57. Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.
Withoff S; de Vries EG; Keith WN; Nienhuis EF; van der Graaf WT; Uges DR; Mulder NH
Br J Cancer; 1996 Dec; 74(12):1869-76. PubMed ID: 8980384
[TBL] [Abstract][Full Text] [Related]
58. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action.
Sinha BK; Haim N; Dusre L; Kerrigan D; Pommier Y
Cancer Res; 1988 Sep; 48(18):5096-100. PubMed ID: 2842045
[TBL] [Abstract][Full Text] [Related]
59. Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters KB; Brown JM
Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
[TBL] [Abstract][Full Text] [Related]
60. Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response.
Guinee DG; Holden JA; Benfield JR; Woodward ML; Przygodzki RM; Fishback NF; Koss MN; Travis WD
Cancer; 1996 Aug; 78(4):729-35. PubMed ID: 8756364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
